SE0200005L - Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet - Google Patents

Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet

Info

Publication number: SE0200005L
Authority: SE; Sweden
Prior art keywords: pregnant woman; labor; treatment; myometrium; cervix
Prior art date: 2002-01-02

Application number

SE0200005A

Other languages

Unknown language ( )

English (en)

Other versions

SE521676C2 (sv

SE0200005D0 (sv

Inventor

Gunvor Ekman-Ordeberg

Anders Malmstroem

Original Assignee

Karolinska Innovations Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-02

Filing date

2002-01-02

Publication date

2003-07-03

2002-01-02 Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab

2002-01-02 Priority to SE0200005A priority Critical patent/SE521676C2/sv

2002-01-02 Publication of SE0200005D0 publication Critical patent/SE0200005D0/sv

2003-01-02 Priority to IL16266403A priority patent/IL162664A0/xx

2003-01-02 Priority to DE60320931T priority patent/DE60320931D1/de

2003-01-02 Priority to SI200331314T priority patent/SI1461049T1/sl

2003-01-02 Priority to CNB038019442A priority patent/CN100341518C/zh

2003-01-02 Priority to ES03700633T priority patent/ES2306852T3/es

2003-01-02 Priority to HK05108458.3A priority patent/HK1076389B/xx

2003-01-02 Priority to CA2472093A priority patent/CA2472093C/en

2003-01-02 Priority to JP2003556076A priority patent/JP4434741B2/ja

2003-01-02 Priority to PT03700633T priority patent/PT1461049E/pt

2003-01-02 Priority to NZ53385603A priority patent/NZ533856A/xx

2003-01-02 Priority to US10/500,284 priority patent/US7407945B2/en

2003-01-02 Priority to PCT/SE2003/000004 priority patent/WO2003055499A1/en

2003-01-02 Priority to KR1020047010488A priority patent/KR100958691B1/ko

2003-01-02 Priority to PL370428A priority patent/PL206458B1/pl

2003-01-02 Priority to DK03700633T priority patent/DK1461049T3/da

2003-01-02 Priority to AU2003201787A priority patent/AU2003201787B2/en

2003-01-02 Priority to AT03700633T priority patent/ATE395067T1/de

2003-01-02 Priority to EP03700633A priority patent/EP1461049B1/en

2003-07-03 Publication of SE0200005L publication Critical patent/SE0200005L/sv

2003-11-25 Publication of SE521676C2 publication Critical patent/SE521676C2/sv

2004-06-21 Priority to IL162664A priority patent/IL162664A/en

2004-06-24 Priority to ZA2004/05015A priority patent/ZA200405015B/en

2004-07-27 Priority to NO20043190A priority patent/NO332702B1/no

2008-07-07 Priority to US12/168,683 priority patent/US8207145B2/en

2008-08-13 Priority to CY20081100861T priority patent/CY1108260T1/el

2012-05-09 Priority to US13/467,918 priority patent/US8524688B2/en

Links

229920002683 Glycosaminoglycan Polymers 0.000 title 1
230000035935 pregnancy Effects 0.000 title 1
230000002265 prevention Effects 0.000 title 1
210000003679 cervix uteri Anatomy 0.000 abstract 3
210000000754 myometrium Anatomy 0.000 abstract 3
239000003055 low molecular weight heparin Substances 0.000 abstract 2
229940127215 low-molecular weight heparin Drugs 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
102000004411 Antithrombin III Human genes 0.000 abstract 1
108090000935 Antithrombin III Proteins 0.000 abstract 1
229960005348 antithrombin iii Drugs 0.000 abstract 1
238000009109 curative therapy Methods 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
230000014508 negative regulation of coagulation Effects 0.000 abstract 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 abstract 1
230000037452 priming Effects 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SE0200005A 2002-01-02 2002-01-02 Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet SE521676C2 (sv)

Priority Applications (25)

Application Number	Priority Date	Filing Date	Title
SE0200005A SE521676C2 (sv)	2002-01-02	2002-01-02	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
EP03700633A EP1461049B1 (en)	2002-01-02	2003-01-02	Use of sulfated glycosaminoglycans for establishing effective labor in women
PCT/SE2003/000004 WO2003055499A1 (en)	2002-01-02	2003-01-02	Use of sulfated glycosaminoglycans for establishing effective labor in women
PL370428A PL206458B1 (pl)	2002-01-02	2003-01-02	Zastosowanie siarczanowanych glikozoaminoglikanów w położnictwie
SI200331314T SI1461049T1 (sl)	2002-01-02	2003-01-02	Uporaba sulfatiranih glikozaminoglikanov za uvedbo učinkovitega poroda pri ženskah
CNB038019442A CN100341518C (zh)	2002-01-02	2003-01-02	硫酸化葡糖胺聚糖在制备预防和治疗足月分娩进展缓慢的药物制剂中的用途
ES03700633T ES2306852T3 (es)	2002-01-02	2003-01-02	Uso de glicosaminoglicanos sulfatados para establecer un parto efectivo en mujeres.
HK05108458.3A HK1076389B (en)	2002-01-02	2003-01-02	Use of sulfated glycosaminoglycans for the manufacture of a pharmaceutical preparation for the prevention and treatment of slow progress of term labor
CA2472093A CA2472093C (en)	2002-01-02	2003-01-02	Use of sulfated glycosaminoglycans for establishing effective labor in women
JP2003556076A JP4434741B2 (ja)	2002-01-02	2003-01-02	女性の有効な分娩を確立するための硫酸化グリコサミノグリカンの使用
PT03700633T PT1461049E (pt)	2002-01-02	2003-01-02	Utilização de glicosaminoglicanos sulfatados para estabelecer um parto efectivo em mulheres
NZ53385603A NZ533856A (en)	2002-01-02	2003-01-02	Sulphated glycosaminoglycans with an anticoagulant activity of 100 BP units/mg or less for prophylactic priming or curative treatment of the cervix and myometrium during labour
US10/500,284 US7407945B2 (en)	2002-01-02	2003-01-02	Use of sulfated glycosaminoglycans for establishing effective labor in women
IL16266403A IL162664A0 (en)	2002-01-02	2003-01-02	Use of sulfated glycosaminoglycans for establishing effective labor inwomen
KR1020047010488A KR100958691B1 (ko)	2002-01-02	2003-01-02	임부의 효과적인 분만을 유도하기 위한 황산화글리코스아미노글리칸의 용도
DE60320931T DE60320931D1 (de)	2002-01-02	2003-01-02	Verwendung von sulfatierten glykosaminoglykanen zur herbeiführung von effektiven wehen bei frauen
DK03700633T DK1461049T3 (da)	2002-01-02	2003-01-02	Anvendelse af sulfaterede glycosaminoglykoner til etablering af effektiv födsel hos kvinder
AU2003201787A AU2003201787B2 (en)	2002-01-02	2003-01-02	Use of sulfated glycosaminoglycans for establishing effective labor in women
AT03700633T ATE395067T1 (de)	2002-01-02	2003-01-02	Verwendung von sulfatierten glykosaminoglykanen zur herbeiführung von effektiven wehen bei frauen
IL162664A IL162664A (en)	2002-01-02	2004-06-21	Use of sulfated glycosaminoglycans for the manufacture of a pharmaceutical preparation for the prevention and treatment of slow progress of term labor
ZA2004/05015A ZA200405015B (en)	2002-01-02	2004-06-24	Use of sulfated glycosaminoglycans for establishing effective labor in women
NO20043190A NO332702B1 (no)	2002-01-02	2004-07-27	Anvendelse av sulfaterte glykosaminoglykaner for fremstilling av et farmasoytisk preparat for forebygging og behandling av langsom utvikling av fodselsveer hos kvinner
US12/168,683 US8207145B2 (en)	2002-01-02	2008-07-07	Use of sulfated glycosaminoglycans for establishing effective labor in women
CY20081100861T CY1108260T1 (el)	2002-01-02	2008-08-13	Χρηση θειικων γλυκοζαμινογλυκανιων για την πραγματοποιηση αποτελεσματικου τοκετου σε γυναικες
US13/467,918 US8524688B2 (en)	2002-01-02	2012-05-09	Use of sulfated glycosaminoglycans for establishing effective labor in women

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE0200005A SE521676C2 (sv)	2002-01-02	2002-01-02	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet

Publications (3)

Publication Number	Publication Date
SE0200005D0 SE0200005D0 (sv)	2002-01-02
SE0200005L true SE0200005L (sv)	2003-07-03
SE521676C2 SE521676C2 (sv)	2003-11-25

Family

ID=20286575

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE0200005A SE521676C2 (sv)	2002-01-02	2002-01-02	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet

Country Status (21)

Country	Link
US (3)	US7407945B2 (sv)
EP (1)	EP1461049B1 (sv)
JP (1)	JP4434741B2 (sv)
KR (1)	KR100958691B1 (sv)
CN (1)	CN100341518C (sv)
AT (1)	ATE395067T1 (sv)
AU (1)	AU2003201787B2 (sv)
CA (1)	CA2472093C (sv)
CY (1)	CY1108260T1 (sv)
DE (1)	DE60320931D1 (sv)
DK (1)	DK1461049T3 (sv)
ES (1)	ES2306852T3 (sv)
IL (2)	IL162664A0 (sv)
NO (1)	NO332702B1 (sv)
NZ (1)	NZ533856A (sv)
PL (1)	PL206458B1 (sv)
PT (1)	PT1461049E (sv)
SE (1)	SE521676C2 (sv)
SI (1)	SI1461049T1 (sv)
WO (1)	WO2003055499A1 (sv)
ZA (1)	ZA200405015B (sv)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE521676C2 (sv)	2002-01-02	2003-11-25	Dilafor Ab	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2005007223A2 (en) *	2003-07-16	2005-01-27	Sasha John	Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
WO2013095215A1 (en)	2011-12-19	2013-06-27	Dilaforette Ab	Low anticoagulant heparins
PT2794665T (pt) *	2011-12-19	2018-01-24	Dilafor Ab	Glicosaminoglicanos não anticoagulativos que compreendem unidade repetitiva de dissacáridos e sua utilização médica
UA117908C2 (uk) *	2012-03-26	2018-10-25	Ділафор Аб	Застосування гепарину або гепарансульфату для індукції пологів
NZ631279A (en) *	2012-03-26	2016-06-24	Dilafor Ab	Method for treatment of labor arrest
MY192330A (en) *	2012-05-08	2022-08-17	Dilafor Ab	Treatment of postpartum haemorrhage with chemically modified heapin or heparan sulphate and a uterotonic agent
CA2879763C (en)	2012-08-03	2020-12-01	Simon LOWRY	The use of antithrombin in extracorporeal membrane oxygenation
CA3169421A1 (en)	2020-02-17	2021-08-26	Dilafor Ab	Tafoxiparin for the treatment of preeclampsia
US20230355658A1 (en)	2022-05-03	2023-11-09	Dilafor Ab	Medical use of tafoxiparin
EP4272749A1 (en)	2022-05-03	2023-11-08	Dilafor AB	New medical use of tafoxiparin

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5223263A (en) *	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
EP0209924A1 (en) *	1985-07-12	1987-01-28	Akzo N.V.	New anti-trombosis agent based on glycosaminoglycan, process for its preparation, and pharmaceutical compositions
US4916122A (en) *	1987-01-28	1990-04-10	University Of Georgia Research Foundation, Inc.	3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) *	1987-01-28	1993-03-02	University Of Georgia Research Foundation, Inc.	3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
SE8702254D0 (sv)	1987-05-29	1987-05-29	Kabivitrum Ab	Novel heparin derivatives
GB8719367D0 (en) *	1987-08-15	1987-09-23	Wellcome Found	Therapeutic compounds
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6020322A (en) *	1993-11-09	2000-02-01	Pro-Neuron, Inc.	Acyl deoxyribonucleoside derivatives and uses thereof
US5470838A (en) *	1987-10-28	1995-11-28	Pro-Neuron, Inc.	Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5736531A (en) *	1987-10-28	1998-04-07	Pro-Neuron, Inc.	Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5411947A (en) *	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) *	1989-11-22	1993-03-16	Vical, Inc.	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5543389A (en) *	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization	Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) *	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) *	1990-11-01	1993-10-26	State Of Oregon	Covalent polar lipid-peptide conjugates for immunological targeting
US5149794A (en) *	1990-11-01	1992-09-22	State Of Oregon	Covalent lipid-drug conjugates for drug targeting
US5280016A (en)	1991-03-29	1994-01-18	Glycomed Incorporated	Non-anticoagulant heparin derivatives
US5554728A (en) *	1991-07-23	1996-09-10	Nexstar Pharmaceuticals, Inc.	Lipid conjugates of therapeutic peptides and protease inhibitors
SE9302135D0 (sv) *	1993-06-18	1993-06-18	Kabi Pharmacia Ab	New pharmaceutical composition
US5587362A (en) *	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
US5559101A (en) *	1994-10-24	1996-09-24	Genencor International, Inc.	L-ribofuranosyl nucleosides
DK0831852T3 (da) *	1995-06-07	2007-03-19	Univ Emory	Nukleosider med anti-hepatitis B-virusaktivitet
US6025335A (en) *	1995-09-21	2000-02-15	Lipitek International, Inc.	L-Nucleoside Dimer Compounds and therapeutic uses
US5767269A (en) *	1996-10-01	1998-06-16	Hamilton Civic Hospitals Research Development Inc.	Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
JP4203611B2 (ja) *	1996-10-15	2009-01-07	生化学工業株式会社	子宮頸管熟化剤
JP4412756B2 (ja)	1998-02-26	2010-02-10	生化学工業株式会社	新規多糖誘導体、その製造法及びそれを有効成分とする医薬組成物
BR9911457A (pt) *	1998-06-24	2001-12-11	Univ Emory	Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
IL127896A0 (en) *	1998-12-31	1999-10-28	Gail Laster	A novel treatment for preeclampsia and related diseases
JP2000309544A (ja) *	1999-02-25	2000-11-07	Seikagaku Kogyo Co Ltd	早産または流産防止剤および子宮頚管熟化抑制剤ならびにヒアルロニダーゼの阻害剤
SE521676C2 (sv)	2002-01-02	2003-11-25	Dilafor Ab	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet

2002
- 2002-01-02 SE SE0200005A patent/SE521676C2/sv unknown
2003
- 2003-01-02 PT PT03700633T patent/PT1461049E/pt unknown
- 2003-01-02 AU AU2003201787A patent/AU2003201787B2/en not_active Ceased
- 2003-01-02 EP EP03700633A patent/EP1461049B1/en not_active Expired - Lifetime
- 2003-01-02 NZ NZ53385603A patent/NZ533856A/xx not_active IP Right Cessation
- 2003-01-02 CN CNB038019442A patent/CN100341518C/zh not_active Expired - Fee Related
- 2003-01-02 JP JP2003556076A patent/JP4434741B2/ja not_active Expired - Fee Related
- 2003-01-02 DE DE60320931T patent/DE60320931D1/de not_active Expired - Lifetime
- 2003-01-02 DK DK03700633T patent/DK1461049T3/da active
- 2003-01-02 KR KR1020047010488A patent/KR100958691B1/ko not_active Expired - Fee Related
- 2003-01-02 CA CA2472093A patent/CA2472093C/en not_active Expired - Fee Related
- 2003-01-02 AT AT03700633T patent/ATE395067T1/de active
- 2003-01-02 ES ES03700633T patent/ES2306852T3/es not_active Expired - Lifetime
- 2003-01-02 WO PCT/SE2003/000004 patent/WO2003055499A1/en not_active Ceased
- 2003-01-02 IL IL16266403A patent/IL162664A0/xx unknown
- 2003-01-02 PL PL370428A patent/PL206458B1/pl unknown
- 2003-01-02 SI SI200331314T patent/SI1461049T1/sl unknown
- 2003-01-02 US US10/500,284 patent/US7407945B2/en not_active Expired - Fee Related
2004
- 2004-06-21 IL IL162664A patent/IL162664A/en not_active IP Right Cessation
- 2004-06-24 ZA ZA2004/05015A patent/ZA200405015B/en unknown
- 2004-07-27 NO NO20043190A patent/NO332702B1/no not_active IP Right Cessation
2008
- 2008-07-07 US US12/168,683 patent/US8207145B2/en not_active Expired - Fee Related
- 2008-08-13 CY CY20081100861T patent/CY1108260T1/el unknown
2012
- 2012-05-09 US US13/467,918 patent/US8524688B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2472093A1 (en)	2003-07-10
US7407945B2 (en)	2008-08-05
AU2003201787B2 (en)	2008-02-28
PL370428A1 (en)	2005-05-30
NZ533856A (en)	2004-12-24
PT1461049E (pt)	2008-08-22
US20080269165A1 (en)	2008-10-30
KR100958691B1 (ko)	2010-05-18
SI1461049T1 (sl)	2008-12-31
ES2306852T3 (es)	2008-11-16
SE521676C2 (sv)	2003-11-25
AU2003201787A1 (en)	2003-07-15
ATE395067T1 (de)	2008-05-15
US8524688B2 (en)	2013-09-03
SE0200005D0 (sv)	2002-01-02
ZA200405015B (en)	2005-08-31
HK1076389A1 (en)	2006-01-20
CN100341518C (zh)	2007-10-10
JP4434741B2 (ja)	2010-03-17
DK1461049T3 (da)	2008-09-15
IL162664A (en)	2009-06-15
US8207145B2 (en)	2012-06-26
DE60320931D1 (de)	2008-06-26
JP2005513148A (ja)	2005-05-12
CA2472093C (en)	2011-02-22
PL206458B1 (pl)	2010-08-31
CY1108260T1 (el)	2014-02-12
EP1461049A1 (en)	2004-09-29
NO332702B1 (no)	2012-12-10
KR20040075917A (ko)	2004-08-30
NO20043190L (no)	2004-07-26
IL162664A0 (en)	2005-11-20
US20120225843A1 (en)	2012-09-06
WO2003055499A1 (en)	2003-07-10
US20050075314A1 (en)	2005-04-07
CN1612741A (zh)	2005-05-04
EP1461049B1 (en)	2008-05-14

Publication	Publication Date	Title
Zykova et al.	2014	Macrophage stimulating agent soluble yeast β‐1, 3/1, 6‐glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo‐controlled phase II study
Kakkar et al.	1999	Prevention of venous thromboembolism in cancer patients
SE0200005L (sv)	2003-07-03	Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2005055944A3 (en)	2007-06-28	Oligosaccharide compositions and use thereof in the treatment of infection
Middeldorp	2008	Heparin: from animal organ extract to designer drug
DE602004018944D1 (de)	2009-02-26	Verwendung von abführmittel zur behandlung des reizdarmsyndroms
HU190687B (en)	1986-10-28	Process for preparing new antithrombotic of polysaccharide base further pharmaceutical compositions containing such substance as active material
BRPI0413410A (pt)	2006-10-10	co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
CA2519797A1 (en)	2004-10-07	Low molecular weight hyaluronic acid for the treatment of nerve damage
MXPA06003234A (es)	2006-06-08	Citosinas protectoras de los tejidos para el tratamiento y prevencion de la sepsis y la formacion de adhesiones.
KR20190019058A (ko)	2019-02-26	만성 상처의 괴사조직제거 방법
EP1539192A1 (en)	2005-06-15	Composition and kit for the treatment of inflammatory bowel diseases
Chiapuzzo et al.	1988	The use of low molecular weight heparins for post-surgical deep vein thrombosis prevention in orthopaedic patients
HUP0003256A3 (en)	2001-12-28	Use of pentosan polysulfate for preparing medicament useful in treating chronic progressive vascular scarring diseases
EP2810641B1 (en)	2020-02-26	Topical pharmaceutical and medical device preparations containing combinations of sucralfate, hyaluronic acid, arginine and a natural moisturizing agent
Vinazzer	1991	Advantages of low molecular weight heparin over standard heparin: facts and fiction
RU2014149230A (ru)	2016-06-27	Лечение послеродового кровотечения (прк)
Steiner et al.	1989	A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with acenocoumarol) in patients undergoing gynaecological surgery
NO20003510L (no)	2000-09-07	Fett-bindende polymerer
WO2002076393A3 (en)	2003-04-03	Antiagionecic, antitumor, chemopreventative agents
Lee	2003	Anti-thrombotic therapy in cancer patients
FR2811572B1 (fr)	2003-04-18	Utilisation de cyclodextrines polysulfatees pour le traitement de l'arthrose
Manjra	2023	Venous leg ulcers: a literature review
Poseryaev et al.	2020	METHODS OF CONSERVATIVE TREATMENT OF VENOUS TROPHIC ULCERS ON THE OUTPATIENT STAGE
Hee et al.	2005	Overview of current practice and future trends in thromboprophylaxis for general surgery